At close: 28 June at 18:07:38 GMT-4 ...
Mutant p53 as a therapeutic target for the treatment of triple-negative breast cancer: Prelinical investigation with the anti-p53 drug, APR-246. This is an ASCO Meeting Abstract from the 2016 ASCO ...
A Phase I/Ib study of MEK162 (binimetinib), a MEK inhibitor, in combination with carboplatin and pemetrexed in patients with non-squamous NSCLC. This is an ASCO Meeting Abstract from the 2016 ASCO ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results